Navigation Links
Misonix Equipment Funded By Anonymous Patient Donation
Date:9/14/2009

FARMINGDALE, N.Y., Sept. 14 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has announced that a patient, who wishes to remain anonymous, donated the majority of the funds necessary for Christus St. Vincent Medical Center, Santa Fe, NM, to purchase a SonicOne(R) Ultrasonic Wound Cleansing and Debridement System. The System was shipped and installed during the second half of August 2009.

The donation was made by a patient of Christus St. Vincent's Wound and Hyperbaric Center, where she was being treated for chronic, non-healing wounds over a lengthy period of time. During the period of clinical evaluation of the SonicOne, prior to possible purchase, the patient was treated with the SonicOne System, and, in a subsequent visit, it was noted that there was a noticeable improvement in the wound healing process. The patient wanted to move forward with additional SonicOne treatments, but was informed that the clinical evaluation was complete and a decision on purchasing the system would be made when funds became available. The patient inquired as to where a donation might be made so that the equipment could be available for her next appointment. A sizable donation was received by the St. Vincent Hospital foundation the next day, a purchase was made from the Company, and the SonicOne was delivered and installed within one week; in time for the patient's next appointment.

The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.

"Misonix is always pleased to receive testimonials directly from patients who benefit from our products and technology," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "We have always believed that our wound care product platform can make an important contribution to improving patient outcomes and are gratified when real life situations justify our investment in product development and clinical applications."

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

    Investor Relations Contact:
    Kevin McGrath / Cameron Associates, Inc.
    212-245-4577
    Kevin@cameronassoc.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Misonix Announces Attendance At XIV World Congress of Neurological Surgery
2. Misonix Restructures and Expands Sales Organization in Europe
3. Misonix Expands Sales Organization for Direct Sales of the SonicOne(TM) Wound Management System and the SonaStar(R) Ultrasonic Surgical Aspirator in the United States
4. Misonix Announces the Sale of Its Labcaire Business for up to $5.6 Million
5. Misonix Receives First Award for Forensic Equipment in China
6. Misonix Announces Participation in 2nd International Workshop on Focal Therapy
7. Misonix Subsidiary, Sonora Medical Systems, Achieves ISO 17025 Accreditation
8. Misonix Announces the Purchase of Patents From ProRhythm, Inc.
9. Misonix Announces Attendance at 22nd Annual Symposium on Advanced Wound Care
10. Misonix Announces Participation in Annual Diabetic Foot Global Conference
11. Misonix Reports Earnings for the Three and Nine Months Ended March 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2017)... ... , ... Scientists from the University of Exeter reported this month ... equivalent to a medium-paced run for pre-menopausal women, or a slow jog for post-menopausal ... spine care, I understand the importance exercise can play on improving bone health. Although ...
(Date:7/23/2017)... Fla. (PRWEB) , ... July 23, 2017 , ... ... M.D., has joined Florida Pain Relief Group – Melbourne, a practice owned by ... board certification in interventional pain management, Dr. Stern also is certified in pediatrics, ...
(Date:7/22/2017)... ... July 22, 2017 , ... The arthroscopic superior capsule ... opportunity to return to sports and jobs that require heavy physical work, as ... Annual Meeting in Toronto, Ontario, Canada. , “We studied 100 patients ...
(Date:7/21/2017)... Orange Park, FL (PRWEB) , ... July 21, ... ... that provides insurance management assistance and financial planning services to families and business ... in a charity event that promises to provide support to area adults with ...
(Date:7/21/2017)... ... , ... Hospital M&A activity slowed in the second quarter of 2017, according ... to 23 in the second quarter, up 15% from the 20 publicly announced acquisitions ... in the year-ago second quarter. Only four of the transactions disclosed a purchase price ...
Breaking Medicine News(10 mins):
(Date:7/6/2017)... , July 6, 2017 ThriveRx, the nutrition division of ... their families to thrive on nutrition support. To celebrate its ... new site has a fresh new look with improved organization to create ... ... ...
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of oral drug ... the Israel Securities Authority to dual-list its common stock on ... commence trading on the TASE on July 12, 2017 under ... the Company, it is expected that Oramed will be included ...
(Date:7/5/2017)... , July 5, 2017   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade cell ... freeze media ("BioLife"), today announced that it has ... debt holder and largest shareholder, to modify its existing ... Pursuant to the modification, WAVI agreed to exchange its ...
Breaking Medicine Technology: